Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
As of close of business last night, Cytek BioSciences Inc’s stock clocked out at $2.49, down -3.11% from its previous closing price of $2.57. In other words, the price has decreased by -$3.11 from its previous closing price. On the day, 1.13 million shares were traded.
Ratios:
To gain a deeper understanding of CTKB’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.19 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 18.03. For the most recent quarter (mrq), Quick Ratio is recorded 4.95 and its Current Ratio is at 5.62. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.05.
On January 31, 2025, Goldman Downgraded its rating to Sell which previously was Buy and also lowered its target price recommendation from $7 to $4.50.
On December 14, 2023, Stephens started tracking the stock assigning a Overweight rating and target price of $9.Stephens initiated its Overweight rating on December 14, 2023, with a $9 target price.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 1.60 while its Price-to-Book (P/B) ratio in mrq is 0.84.
Stock Price History:
Over the past 52 weeks, CTKB has reached a high of $7.63, while it has fallen to a 52-week low of $2.37. The 50-Day Moving Average of the stock is -29.61%, while the 200-Day Moving Average is calculated to be -51.19%.
Shares Statistics:
A total of 127.60M shares are outstanding, with a floating share count of 114.70M. Insiders hold about 9.44% of the company’s shares, while institutions hold 60.95% stake in the company.
Earnings Estimates
The firm’s stock currently is rated by 2.0 analysts. The consensus estimate for the next quarter is $0.02, with high estimates of $0.03 and low estimates of $0.01.
Analysts are recommending an EPS of between $0.04 and -$0.05 for the fiscal current year, implying an average EPS of -$0.0. EPS for the following year is $0.07, with 2.0 analysts recommending between $0.13 and $0.01.
Revenue Estimates
In the current quarter, 5 analysts expect revenue to total $46.03M. It ranges from a high estimate of $47.5M to a low estimate of $44.25M. As of the current estimate, Cytek BioSciences Inc’s year-ago sales were $46.62MFor the next quarter, 5 analysts are estimating revenue of $52.18M. There is a high estimate of $52.47M for the next quarter, whereas the lowest estimate is $51.8M.
A total of 6 analysts have provided revenue estimates for CTKB’s current fiscal year. The highest revenue estimate was $199.6M, while the lowest revenue estimate was $196M, resulting in an average revenue estimate of $198.1M. In the same quarter a year ago, actual revenue was $200.45MBased on 6 analysts’ estimates, the company’s revenue will be $213.06M in the next fiscal year. The high estimate is $222.98M and the low estimate is $200.7M.
